Increased sHLA-G Is Associated with Improved COVID-19 Outcome and Reduced Neutrophil Adhesion.
Daria BortolottiValentina GentiliSabrina RizzoGiovanna SchiumaSilvia BeltramiSavino SpadaroGiovanni StrazzaboscoGianluca CampoEdgardo D CarosellaAlberto PapiRoberta RizzoMarco ContoliPublished in: Viruses (2021)
Human leukocyte antigen (HLA) is a group of molecules involved in inflammatory and infective responses. We evaluated blood sHLA-E and sHLA-G levels in hospitalized COVID-19 patients with respiratory failure and their relationship with clinical evolution, changes in endothelial activation biomarker profile, and neutrophil adhesion. sHLA-E, sHLA-G, and endothelial activation biomarkers were quantified by ELISA assay in plasma samples. Neutrophil adhesion to endothelium was assessed in the presence/absence of patients' plasma samples. At admission, plasma levels of sHLA-G and sHLA-E were significantly higher in COVID-19 patients with respiratory failure compared to controls. COVID-19 clinical improvement was associated with increased sHLA-G plasma levels. In COVID-19, but not in control patients, an inverse correlation was found between serum sICAM-1 and E-selectin levels and plasma sHLA-G values. The in vitro analysis of activated endothelial cells confirmed the ability of HLA-G molecules to control sICAM-1 and sE-selectin expression via CD160 interaction and FGF2 induction and consequently neutrophil adhesion. We suggest a potential role for sHLA-G in improving COVID-19 patients' clinical condition related to the control of neutrophil adhesion to activated endothelium.
Keyphrases
- sars cov
- coronavirus disease
- endothelial cells
- respiratory failure
- end stage renal disease
- ejection fraction
- newly diagnosed
- biofilm formation
- extracorporeal membrane oxygenation
- prognostic factors
- respiratory syndrome coronavirus
- nitric oxide
- peritoneal dialysis
- cell migration
- escherichia coli
- staphylococcus aureus
- high throughput
- high glucose
- cystic fibrosis
- intensive care unit